In this webinar we will provide an introductory training on how to introduce a new implant/invasive device in an inpatient setting:
- Reimbursement landscape in Belgium :
- Country-specific drivers and barriers for adoption;
- Past and forthcoming changes related to hospital finance reform;
- Market access pathways for implants and invasive devices:
- Step-by-step description of the major reimbursement processes in Belgium;
- Administrative preliminary stages to proper reimbursement request: registrations and notifications;
- Latest changes in the reimbursement processes.
- Innovation funding in the Belgian healthcare system;
- Sharing of experiences;
- Interactive Q&A.
- Michel Verhasselt, Founder and CEO of MediTech Access
- Audrey Ortiz, Partner of MediTech Access
Michel Verhasselt founded MediTech Access in 2012. He holds a Master's degree in Business Administration and Health Economics from the Catholic University of Lille. He has a 30-year experience in the field of Health Economics, HTA, DRG coding and reimbursement, especially within the medical device industry, making him an expert. He conducts public affairs and market access activities for France, Belgium and Switzerland. Michel has successfully established CED arrangements for several companies.
Audrey Ortiz started her training as an engineer, in preparatory class for “Grandes Ecoles” and ended up earning a PharmD and a Master Degree in Health Economics from Paris-Dauphine University. She has work experience at large pharmaceutical firms (Sanofi and Roche) and mid-sized ones (Celgene and Hospira). Determined to further develop her skills in the MedTech field after an empowering experience at Synergus, she joined MediTech Access, a consulting company highly specialized in Market Access and Health Economics in France, Belgium and Switzerland. Recruited as a consultant, she quickly became Manager and Partner. She is currently responsible for managing projects in France, leading the activities in Belgium and Switzerland and for developing the European activities. For the past five years, she has been successfully managing the funding and the reimbursement of implants and invasive devices in Belgium.